生存质量分析在干扰素治疗慢性丙型肝炎疗效评价中的应用

发布时间：2018-05-12 17:21

本文选题：生活质量 + 丙型肝炎　；参考：《中国全科医学》2015年31期

【摘要】：目的探讨生存质量(QOL)分析在不同类型干扰素(INF)治疗慢性丙型肝炎(CHC)疗效评价中的意义。方法收集2011年2月—2014年5月于宽城满族自治县医院住院,符合纳入与排除标准且文化程度均为初中以上的患者140例。根据使用IFN类型分为A组(62例)、B组(78例)。A组给予聚乙二醇干扰素α(Peg IFNα)2a联合利巴韦林治疗,B组给予干扰素α-2b(IFNα-2b)联合利巴韦林治疗。检测两组患者丙型肝炎病毒(HCV)RNA水平及HCV基因型、病毒学应答情况,并进行慢性肝病特异性量表(CLDQ)评分。结果两组患者HCV RNA水平比较,差异无统计学意义(P0.05)。两组不同基因型患者HCV RNA水平比较,差异无统计学意义(P0.05)。A组快速病毒学应答(RVR)、早期病毒学应答(EVR)高于B组(P0.05);两组持续病毒学应答(SVR)比较,差异无统计学意义(P0.05)。A组非1b基因型患者的RVR、EVR高于B组(P0.05)。A组疲劳(FA)评分高于B组(P0.05)。两组1b基因型患者的情感(EF)、系统症状(SS)、焦虑度(WO)评分比较,差异有统计学意义(P0.05)。A组非1b基因型患者的活动能力(AC)、EF、SS、WO评分低于B组(P0.05)。结论引入QOL分析对不同类型INF治疗CHC患者的疗效进行综合评价,IFNα-2b的疗效优势更显著,非1b基因型患者或可优先选择IFNα-2b联合利巴韦林治疗。
[Abstract]:Objective to evaluate the effect of different types of interferon (INFN) in the treatment of chronic hepatitis C (CHCC) by quality of life (QOL) analysis. Methods 140 patients who were hospitalized in Kuancheng Manchu Autonomous County Hospital from February 2011 to May 2014 and met the criteria of inclusion and exclusion were collected. According to the type of IFN, the patients in group A were divided into group A (n = 62) and group B (n = 78). Group A was treated with peg IFN 伪 2a and ribavirin in combination with ribavirin (group B) and ribavirin. The HCV RNA levels, HCV genotypes, virological responses and CLDQs were measured in the two groups. Results there was no significant difference in HCV RNA level between the two groups (P 0.05). There was no significant difference in HCV RNA levels between the two groups with different genotypes. There was no significant difference in the rapid virological response (RV), the early virological response (EVR) was higher in group A than that in group B (P 0.05), and the continuous virological response was higher in group A than in group B. No significant difference was found in the RVRV EVR scores of patients with non-1b genotypes in group P0.05. A were higher than those in group B (P 0.05) and the scores of FAR in group A were higher than those in group B (P 0.05) and the scores of FRA in group A were higher than those in group B (P 0.05). There was a significant difference in the scores of affective disorder, systemic symptom and anxiety (WO) between the two groups. There was a significant difference in the activity ability of non-1b genotype patients in group A and group A was lower than that in group B (P 0.05). The scores of motor ability in group A were significantly lower than those in group B (P 0.05), and the scores of motor ability in group A were significantly lower than those in group B (P 0.05). Conclusion QOL analysis is more effective in evaluating the efficacy of different types of INF in the treatment of CHC patients. The non-1b genotype patients may be given priority in the treatment of IFN 伪 -2b combined with ribavirin.
【作者单位】：宽城满族自治县医院肝病科;北京大学肝病研究所;北京大学人民医院肝病科;
【分类号】：R512.63

【参考文献】